Apr 252011
Bayer HealthCare Pharmaceuticals is aware of two studies published in The British Medical Journal. These papers are “Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database” by Lianne Parkin et al (1); and
See the article here:
Bayer affirms the positive benefit-risk profile of its drospirenone- containing oral contraceptives